Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

FDA Flags Another Safety Issue With J&J's Abiomed Impella Controllers

27 August 2026 · By · Wire by Fusion42

Published

27 August 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at insights.citeline.com →

◆ Verified

Fusion42 · 27 August 2026 · Fusion42 review

The FDA has identified an additional safety concern with Johnson & Johnson's Abiomed Impella heart pump controllers, which may impact device usage and regulatory scrutiny.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You face tighter compliance and oversight demands as the FDA flags new safety issues with leading cardiac support devices. Expect shifts in procurement and device approvals to affect your go-to-market strategies.

◆ Coverage

3 sources · 27 Aug 2026

◆ Related on Wire

◆ Topics

Medtechfdamedtechdevice-safetyregulatory-updatecardiac-support